Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemoradiotherapy with PBSC Rescue in NHL
NCT00002510Phase 2Completed
- Sponsor
- Temple University
- Start
- Apr 1992
- Primary completion
- Jun 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide in non-Hodgkin lymphoma (NHL), sponsored by Temple University. Primary endpoints: Overall Survival and Progression-Free Survival. Started Apr 1992; status: completed.
02
Drugs
etoposide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002510.